The high-tech sealant manufacturer will showcase its MS971 Multi-purpose MS Polymer Sealant and MS973 Fast Dry MS Polymer Sealant and discuss OEM/ODM services and product customization with international building materials buyers.
DUBAI, UAE, Oct. 26, 2026 /PRNewswire/ -- Kastar, a Chinese high-tech sealant manufacturer and contributor to the country's silane-modified polymer (MS Polymer) sealant standards, will present its MS polymer sealant technology and manufacturing capabilities at The Big 5 Global 2026, taking place November 23 to 26 at Dubai World Trade Centre. At Booth 8E 331A in the International Pavilion, Za'abeel Hall 3, the company will feature its MS971 Multi-purpose MS Polymer Sealant and MS973 Fast Dry MS Polymer Sealant for international distributors, building materials brands and construction industry buyers.
KASTAR develops MS polymer sealants using its in-house silane-terminated polymer synthesis technology.
In-House MS Polymer Technology
KASTAR has accumulated 28 years of experience in adhesive and sealant manufacturing. Its research and development work includes MS polymer materials and silicone based products, with a team of 28 dedicated R&D engineers and a portfolio of 35 patents, according to company figures.
KASTAR develops MS polymer sealants using its in-house silane-terminated polymer synthesis technology. This work supports the formulation of sealants designed to combine adhesion, flexibility and weather resistance across a range of construction applications.
KASTAR will feature two MS polymer products at the exhibition. MS971 Multi-purpose MS Polymer Sealant is a multi-purpose sealant and adhesive for applications including window and door perimeter sealing, roofing, gutters, concrete joints and metal building construction. Its technical data sheet also lists substrates such as aluminum, glass, PVC, wood and concrete. MS973 Fast Dry MS Polymer Sealant is designed for sealing and flexible bonding in applications such as sheet metal fabrication, HVAC systems and vibrating structures.
Both products' technical data sheets list low VOC content, UV resistance and compatibility with water-based paints among their features. Visitors can discuss product specifications, application requirements and available packaging options with KASTAR's team.
Production Capacity and OEM/ODM
KASTAR's manufacturing facilities are located across five Chinese provinces and cover approximately 150,000 square meters in total. According to company figures, its annual production capacity reaches 600,000 metric tons across its product portfolio, including 300,000 metric tons of sealants.
KASTAR's production operations cover polymer raw materials, intermediate materials and finished sealants. The company also supplies products in different formulations and packaging formats to meet the specifications and order requirements of its business customers.
KASTAR offers OEM and ODM services for building materials brands and regional distributors, with options to discuss formulation, color, viscosity and packaging requirements.
KASTAR reports operating a testing center of more than 1,000 square meters with CMA certification and applying 12 inspection stages across its production process. The company reports an outgoing product defect rate of no more than 0.03 percent. These figures reflect the company's stated quality control practices, with the measurement period and calculation methodology available for confirmation upon request.
"One of the biggest problems with sealants is that they can get dirty or develop mold over time. We've found KASTAR's products to be a good solution to this problem," said Elton D, a KASTAR customer.
Global Supply and Distribution
KASTAR exports products to 69 countries and regions and reports having served more than 1,000 customers worldwide. The company also reports nearly two decades as an Alibaba Gold Supplier and established distribution channels in a number of European markets.
KASTAR's product range also includes silicone and acrylic sealants, fire-resistant sealants, tile grouts, construction adhesives and waterproof coatings.
At Booth 8E 331A, visitors can meet the KASTAR team to review MS971 Multi-purpose MS Polymer Sealant and MS973 Fast Dry MS Polymer Sealant specifications and discuss OEM/ODM requirements.
Meet KASTAR at The Big 5 Global 2026
Event: The Big 5 Global 2026
Dates: November 23 to 26, 2026
Venue: Dubai World Trade Centre, Dubai, United Arab Emirates
Booth: 8E 331A
Location: International Pavilion, Za'abeel Hall 3
About KASTAR
Founded in 1997 and headquartered in Foshan, China, Kastar is a core brand of Kater Adhesive Industrial Co., Ltd., a national high-tech manufacturer specializing in construction sealants and adhesives, with a focus on MS polymer technologies. The brand offers a broad portfolio of solutions, including hybrid MS sealants, polyether sealants, silicone sealants, fireproof sealants, and nail-free sealants, serving both standard and customized construction applications.
Through the KASTAR brand, the company serves international markets with construction sealing and bonding products.
Media Contact:
Email: construction@kater-adhesive.cn
Website: https://www.kastargrout.com/
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
KASTAR Takes Its In-House MS Polymer Technology to The Big 5 Global 2026
- Automated system enables rapid, reproducible formulation screening with minimal sample consumption
- Completes the NanoCalibur® Series (Mini, Lab, Pro, GMP), supporting a seamless scale-up path from early research to GMP manufacturing
BOSTON, Oct. 26, 2026 /PRNewswire/ -- MEPSGEN US, Inc., a global innovator in drug delivery system platforms, today announced the launch of NanoCalibur® Mini, an automated system for small-volume nanoparticle formulation designed for early-stage drug discovery and development.
Nanoparticles are delivery vehicles that carry therapeutic payloads to target sites in the body, and they are central to next-generation modalities such as mRNA and gene therapies. Early-stage research requires repeated testing of many raw materials and process conditions, so the ability to generate fast, consistent results from limited material is essential.
NanoCalibur® Mini formulates lipid nanoparticles (LNPs) and polymeric nanoparticles at volumes of 0.1–3 mL. Built on MEPSGEN's proprietary microfluidic technology, it delivers precise, stable microfluidic flow control for rapid and highly reproducible formulation. Researchers can choose between two single-use microfluidic cartridges, 0.1–0.4 mL and 0.4–3 mL, to match their application, from early formulation screening through a range of preclinical studies. By enabling many formulation conditions to be tested quickly with minimal material, Mini helps accelerate development timelines while reducing reagent consumption and experimental costs.
One production architecture, from discovery to GMP
With the addition of Mini, the NanoCalibur® Series now spans four systems (Mini, Lab, Pro, and GMP), allowing customers to select the right platform for their development stage and production scale.
The defining feature of the series is a consistent formulation environment at every scale. NanoCalibur® Mini to Lab and to GMP uses the same microfluidic mixing pattern, with the same structure and dimensions. Rather than redesigning the mixer or changing the formulation conditions as production grows, NanoCalibur® increases throughput by parallelizing identical mixing units. This design is intended to reduce the need for process re-optimization during scale-up and technology transfer, while preserving nanoparticle quality and batch-to-batch reproducibility.
Protecting payload integrity at scale
In large-scale nanoparticle manufacturing, the high flow rates required for throughput can generate shear forces that damage sensitive payloads such as mRNA and reduce the potency. The NanoCalibur® Series is engineered to maintain stable shear conditions as production scales, helping preserve payload integrity and deliver consistent nanoparticle quality. More importantly, preserving payload potency will have the high potential to reduce the dose required for therapeutic effect, possibly addressing the high-dosage toxicity such as LNPs.
Launch promotion
To mark the launch of NanoCalibur® Mini, MEPSGEN will run a series of promotional offers through the end of the year for research institutions and pharmaceutical and biotechnology companies evaluating the system. Details will be announced on the MEPSGEN website and the company's official LinkedIn page.
"With NanoCalibur® Mini, we have extended our product lineup so that we can support customers more precisely at every stage, from early research through GMP manufacturing," said YongTae Kim, CEO of MEPSGEN. "We will continue to broaden the applications and customer base of the NanoCalibur® Series and strengthen our position in the global nanomedicine manufacturing market."
About MEPSGEN
MEPSGEN is a biotech company headquartered in Seoul, South Korea, with office in Cambridge, MA. The company was co-founded in 2019 by current CEO YongTae (Tony) Kim and Professor Robert Langer from MIT, a world-renowned expert in drug delivery and biomaterials who has pioneered numerous breakthroughs in controlled-release systems.
The company specializes in microphysiological system (MPS) and drug delivery system platforms based on its proprietary microfluidics technology. Its NanoCalibur® Series offers scalable nanoparticle formulation systems that support drug discovery, preclinical research, and GMP manufacturing, while its MPS platforms, including the MEPS-X Series and ProMEPS®, recreate the physiological function of human organs for New Approach Methodologies (NAMs). Together, they help pharmaceutical and biotech companies, universities, hospitals, and research institutions improve the efficiency and success rate of drug development.
For more information, please visit www.mepsgen.com or reach out to info@mepsgen-us.com
BOSTON, Oct. 26, 2026 /PRNewswire/ -- MEPSGEN US, Inc., a global innovator in drug delivery system platforms, today announced the launch of NanoCalibur® Mini, an automated system for small-volume nanoparticle formulation designed for early-stage drug discovery and development.
Nanoparticles are delivery vehicles that carry therapeutic payloads to target sites in the body, and they are central to next-generation modalities such as mRNA and gene therapies. Early-stage research requires repeated testing of many raw materials and process conditions, so the ability to generate fast, consistent results from limited material is essential.
NanoCalibur® Mini formulates lipid nanoparticles (LNPs) and polymeric nanoparticles at volumes of 0.1–3 mL. Built on MEPSGEN's proprietary microfluidic technology, it delivers precise, stable microfluidic flow control for rapid and highly reproducible formulation. Researchers can choose between two single-use microfluidic cartridges, 0.1–0.4 mL and 0.4–3 mL, to match their application, from early formulation screening through a range of preclinical studies. By enabling many formulation conditions to be tested quickly with minimal material, Mini helps accelerate development timelines while reducing reagent consumption and experimental costs.
One production architecture, from discovery to GMP
With the addition of Mini, the NanoCalibur® Series now spans four systems (Mini, Lab, Pro, and GMP), allowing customers to select the right platform for their development stage and production scale.
The defining feature of the series is a consistent formulation environment at every scale. NanoCalibur® Mini to Lab and to GMP uses the same microfluidic mixing pattern, with the same structure and dimensions. Rather than redesigning the mixer or changing the formulation conditions as production grows, NanoCalibur® increases throughput by parallelizing identical mixing units. This design is intended to reduce the need for process re-optimization during scale-up and technology transfer, while preserving nanoparticle quality and batch-to-batch reproducibility.
Protecting payload integrity at scale
In large-scale nanoparticle manufacturing, the high flow rates required for throughput can generate shear forces that damage sensitive payloads such as mRNA and reduce the potency. The NanoCalibur® Series is engineered to maintain stable shear conditions as production scales, helping preserve payload integrity and deliver consistent nanoparticle quality. More importantly, preserving payload potency will have the high potential to reduce the dose required for therapeutic effect, possibly addressing the high-dosage toxicity such as LNPs.
Launch promotion
To mark the launch of NanoCalibur® Mini, MEPSGEN will run a series of promotional offers through the end of the year for research institutions and pharmaceutical and biotechnology companies evaluating the system. Details will be announced on the MEPSGEN website and the company's official LinkedIn page.
"With NanoCalibur® Mini, we have extended our product lineup so that we can support customers more precisely at every stage, from early research through GMP manufacturing," said YongTae Kim, CEO of MEPSGEN. "We will continue to broaden the applications and customer base of the NanoCalibur® Series and strengthen our position in the global nanomedicine manufacturing market."
About MEPSGEN
MEPSGEN is a biotech company headquartered in Seoul, South Korea, with office in Cambridge, MA. The company was co-founded in 2019 by current CEO YongTae (Tony) Kim and Professor Robert Langer from MIT, a world-renowned expert in drug delivery and biomaterials who has pioneered numerous breakthroughs in controlled-release systems.
The company specializes in microphysiological system (MPS) and drug delivery system platforms based on its proprietary microfluidics technology. Its NanoCalibur® Series offers scalable nanoparticle formulation systems that support drug discovery, preclinical research, and GMP manufacturing, while its MPS platforms, including the MEPS-X Series and ProMEPS®, recreate the physiological function of human organs for New Approach Methodologies (NAMs). Together, they help pharmaceutical and biotech companies, universities, hospitals, and research institutions improve the efficiency and success rate of drug development.
For more information, please visit www.mepsgen.com or reach out to info@mepsgen-us.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
MEPSGEN Launches NanoCalibur® Mini for Small-Volume Nanoparticle Formulation
